If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-14. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
=== Writing === Garland began writing Dredd during post-production of his other writing credit Sunshine, and completed his first draft while serving as an executive producer during filming of 28 Weeks Later. Garland's draft revolved around one of Dredd's main enemies, the undead Judge Death. He described the story as a "riff on the whole Judge system", but that it did not work because the Judge system had not yet been established and required too much knowledge about the Judge Dredd comic from the audience. He also considered the result too surreal and extreme. From this script, Garland decided that the story needed to be more focused and grounded. He instead considered adapting some of the notable Judge Dredd storylines, including "Democracy" (1986) and "Origins" (2006). He decided to avoid these lengthy tales in favour of a shorter, day-in-the-life story about Dredd and his function as a cop in the dystopian environment of Mega-City One. When developing the Judge Dredd character, Garland tried to closely follow that of the comic-book character, who undergoes only small personality changes over a lengthy period of time. He said:
By enabling three-dimensional movement within DMF, the technology can be used even more extensively in biological applications, as it could more accurately mimic 3-D microenvironments. A large benefit of employing this type of method is that it allows for two different environments to be accessible by the droplet, which can be taken advantage of by splitting the microfluidic tasks among the two surfaces. For example, while the lower plane can be used to move droplets, the upper plate can carry out the necessary chemical and/or biological processes. This advantage can be translated into practical experiment protocols in the biological community, such as coupling with DNA amplification. This also allows for the chip to be smaller, and to give researchers more freedom in designing platforms for microdroplet analysis.
is lower than for Sign and Sign. The differences between countries are concentrated in two kinetic constants: the rate of mobilization and the rate of exhaustion calculated for COVID-19 epidemic in 13 countries. These constants for this epidemic in all countries can be extracted by the fitting of the SIRSS model to publicly available data
Sources: en.wikipedia.org
=== Interactions and contraindications === Taking SAM at the same time as some drugs may increase the risk of serotonin syndrome, a potentially dangerous condition caused by having too much serotonin. These drugs include, but are certainly not limited to, dextromethorphan (Robitussin), meperidine (Demerol), pentazocine (Talwin), and tramadol (Ultram). SAM can also interact with many antidepressant medications — including tryptophan and the herbal medicine Hypericum perforatum (St. John's wort) — increasing the potential for serotonin syndrome or other side effects, and may reduce the effectiveness of levodopa for Parkinson's disease. SAM can increase the risk of manic episodes in people who have bipolar disorder.
The author of a 1994 study concluded that it was only in the second half of the 20th century that medical advances have extended the life expectancy of those who live into adulthood. though this is flatly contradicted by 19th- and early 20th-century census and registration data and by estimates for medieval and ancient populations: US and English expectation of remaining years at age 15 for example rose from about 44 in the mid-19th century to 56 by 1950, and has since increased to 65–67; for English landholders (a relatively privileged group) it was 33 years c.1300, while Ulpian's life table for ancient Rome indicates only 30 years. Reliable references to individuals in antiquity who lived past 100 years are quite rare, but they do exist. For instance, Cicero's wife Terentia was reported by Pliny the Elder to have lived from 98 BC to 6 AD, 103 years. Regnal dates of Bronze Age monarchs are notoriously unreliable; the sixth dynasty Egyptian ruler Pepi II is sometimes listed as having lived c. 2278 – c. 2184 BC, as he is said to have reigned for 94 years, but alternative readings cite a reign of just 64 years. Adad-guppi, mother of the last king of the Neo-Babylonian Empire Nabonidus apparently lived from c. 648-544 BC (c. 104 years) according to inscriptions on funeral steles. Zhao Tuo, a Qin Dynasty general, reportedly lived to age 103. Tuoba Liwei also reportedly lived to 103. Marcus Valerius Corvus reportedly lived to 100. Diogenes Laërtius (c.
=== Gestational breast hypertrophy === This same effect can also occur at the onset of pregnancy or between the 16th to 20th week of gestation. When the swelling in the connective tissue occurs after birth, it can negatively impact long term milk supply. The swelling increases with each subsequent pregnancy. The extremely rapid growth of the breasts can result in intense heat. The woman's breasts can generate extraordinary discomfort, turning feverish, red, itchy, and even causing the skin to peel. The swelling can suppress the milk supply, pinching off the milk ducts, and leading to mastitis. Gestational gigantomastia is estimated to occur in 1 out of every 28,000 to 100,000 pregnancies. Breast size in women with gestational breast hypertrophy typically reverts to approximately pre-pregnancy size or near it after pregnancy and cessation of breastfeeding. This is not always the case however and in some only partial reduction in breast size may occur, necessitating surgical breast reduction.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.